Most scary headlines about GLP-1 side effects use the same trick as a “50% off” sale sign: a number that sounds huge until you know what it’s 50% off of. If you’re weighing semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound), the real question isn’t “is this dangerous?” It’s which risks are genuine dealbreakers, which ones you watch for once you’re on it, and which ones are small and adjustable.
That’s what an informed consent conversation is for. And informed consent isn’t just the data. It includes your values, your preferences, and how you feel about a risk, because risk is a very personal choice.
▶ Liked this video? Subscribe to my YouTube channel.
Want this kind of straight talk in your inbox? One short email a week on PMOS / PCOS and metabolic health. No spam, unsubscribe anytime.
In this article
Why do GLP-1 risk headlines sound so scary?
Because most of them report relative risk, and a relative number on its own tells you nothing. Here’s the analogy I want you to carry into this decision, and honestly into a lot of other ones. I give you two 50% off coupons. One is for a single item at the dollar store. The other is 50% off the house of your dreams. Both are accurately 50% off. One barely touches your monthly budget, and the other shapes your financial future. That’s the difference between a relative number and an absolute one.
So when a headline says a GLP-1 “doubles” your risk of something, what you actually want to know is how many people on the drug get it, and how many people off the drug get it. What’s the real difference, and how do you feel about it? That last part is a personal call, not a right or wrong one. Health headlines love relative risk because it sounds dramatic and gets the clicks. That’s the whole trick.
What are GLP-1s actually good for?
They genuinely work. I prescribe them myself, and the evidence is solid for blood sugar, real weight loss, and other metabolic markers for most people while they’re on the medication. Where it’s thinner is research in PMOS (formerly PCOS) specifically. These drugs have changed fast, so a lot of the PMOS studies are on older GLP-1s that are rarely prescribed now. I’m looking forward to newer data on cycle length, ovulation, insulin resistance, and testosterone.
Why does this matter if you have PMOS? Metabolic conditions are more common with it, and that lowers the threshold for when doing something about them makes sense.
One thing comes up pretty consistently when I’m talking with people face to face: these medications make food noise a lot quieter. That quiet can be a bridge to building the skills and foundations underneath. I don’t prescribe them without actively working on that foundation too, because I want to set someone up for the long term.
Most people ask me about nausea first. I think that’s the wrong first question. So let’s sort the risks into three buckets instead: is this a fit for you, the red flags once you’re on it, and the small adjustable stuff.
What are the real dealbreakers for GLP-1s?
Bucket one is fit. Two things are automatic no’s: a personal or family history of medullary thyroid cancer or MEN2 (a rare inherited condition with a very high thyroid cancer risk), and pregnancy or breastfeeding, which is a no for now. A third is a real flag: a prior episode of NAION, a specific type of vision loss, in one eye, because the risk goes up in the other eye.
The thyroid warning comes from rat studies. Rat thyroid cells react to these drugs in a way ours don’t, because ours don’t have the same density of the receptors involved. And we do have human data now. A Scandinavian study followed over 145,000 people on GLP-1s for years and compared them with people on a different diabetes medication. The rate of medullary thyroid cancer was the same in both groups, about 7 in a million people per year either way. So why is it still a hard stop with a personal or family history? Not because we’ve seen it happen on the drug. The animal signal was strong enough that we’re not wanting to test high-risk groups.
The vision loss is NAION, a rare type of vision loss from reduced blood flow to the optic nerve. The first study on it was a smaller one out of Boston, which found people on semaglutide developed it 4 to 7 times more often. That’s the number that made the headlines, and it’s a relative number. A much bigger study of over 400,000 people in Denmark found the real increase is closer to double. In absolute numbers, that’s about 1 in 10,000 people a year without the medication and about 2 in 10,000 with it.
Sit with those numbers. It’s a legitimate increase. The final figure could still move as more studies come in, but the 2026 consensus statement from the North American Neuro-Ophthalmology Society and the American Academy of Ophthalmology reads the evidence as closer to that doubling than the first study suggested, and says cause and effect hasn’t been established yet.
Why take it seriously anyway? NAION isn’t necessarily reversible, and that’s life-changing for the person it happens to. So if you’ve had vision loss in one eye, this needs a real conversation. For everyone else, a simple self check-in: are you up to date on your regular eye exams? Getting a good baseline before you start a GLP-1 is a reasonable step. Separately, bringing blood sugar down very quickly carries its own known eye risk, mostly for people who already have diabetic eye changes, so with metabolic control on these medications, faster isn’t better.
All three of these are rare in absolute terms. That doesn’t shrink the impact on the person who becomes that rare number, which is exactly why they belong in your risk-benefit thinking.
Which GLP-1 side effects need quick action?
Bucket two is the red flags once you’re on it, and the big one is pancreatitis. Persistent, severe abdominal pain, sometimes radiating to your back, with or without vomiting, means call your team and get checked out. Most cases resolve once you stop the medication, but in the moment it can be urgent. It’s not a wait-and-see.
This bucket also holds a warning that’s being walked back, even though it may still be on your label. The Canadian Wegovy label still excludes people with a history of suicide attempts or active suicidal thoughts, and calls for monitoring any new or worsening depression. Honestly, watching for new or worsening depression is good advice during any big change in your life. But the FDA in January 2024 and the EMA in April 2024 each independently reviewed the trial data, the cohort data, and the adverse event reports, and both found no proven cause and effect. The FDA has since asked for the warning to be removed from the label entirely. Health Canada’s label hasn’t caught up yet.
There is a signal in raw safety reporting databases. Those reports are self-reported, though, which is much weaker evidence than the formal reviews.
Which GLP-1 side effects are usually adjustable?
Bucket three is the stuff you hear about most: nausea and other GI symptoms, and low blood sugar, mainly if you’re also on insulin. These are often quite modifiable with the dose. And because these medications slow how fast your stomach empties, tell your surgical team before any procedure.
If something like nausea still isn’t tolerable after dose adjustments, there’s no rule that says you have to continue. There are other options on the table. What to watch for and when to reach out is a conversation with your own provider. If you’ve already made the decision and want the practical version, I’ve laid out what to watch for and what to do when starting a GLP-1 over on PCOS Health Collective.
What about muscle loss on GLP-1s?
It’s the one that doesn’t fit a bucket cleanly, and it gets missed. It isn’t urgent and it isn’t something we adjust the dose for. But with any significant weight loss, some muscle can go too, and if the weight comes back, the muscle doesn’t reliably come back with it. That’s part of the harm of weight cycling up and down: lean tissue gradually goes down with it. Early research on GLP-1s found people who focused on resistance training and enough protein had a lot better body composition than people who didn’t. So it can be mitigated, and I look forward to more research here.
So how do you decide if the risk is worth it?
Start with the numbers, not someone else’s story online. Their experience isn’t going to be yours. Ask yourself what your comfort level is with the more significant risks above, and whether the benefit is worth it for you. Sometimes action is what gives you information you can’t get any other way, and the first step into that is a genuine informed consent conversation about GLP-1 side effects with your prescriber.
I don’t see this as medication or lifestyle. The lifestyle piece is the foundation either way. If you’re still sorting out whether weight is even the right target for you right now, start with ethical PCOS weight loss and the honest middle road.
Watch the full video: Ozempic Side Effects: What’s Actually Reversible (And What’s Not), and subscribe to my YouTube channel so the next one finds you. I also made a GLP-1 Informed Consent Worksheet to go with it: the real numbers, questions to bring to your prescriber, and what to actually watch for. It’s exclusive to Shift Society members and lives in the GLP-1 lesson in the classroom.
Weighing a GLP-1 and want the full worksheet?
The GLP-1 Informed Consent Worksheet is exclusive to members of Shift Society, my community for women who want to really understand their metabolic health, with PMOS (formerly PCOS) at its heart. Step 1: join Shift Society. Step 2: open the GLP-1 lesson in the classroom and grab the worksheet from its resources.
Ready to look at your own picture?
If you’re in BC, a Clarity Call is a free, up to 15 minute fit conversation, not a medical visit. We figure out whether working together makes sense, and I point you in the right direction either way.
Virtual across BC · No pressure, ever
This article is educational, not medical advice or a diagnosis. If something here resonates, bring it to your healthcare team, who can look at it through the lens of your individual health.
Main references
- Pasternak B, et al. Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study. BMJ. 2024. PubMed
- Hathaway JT, et al. Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide. JAMA Ophthalmol. 2024. PubMed
- Grauslund J, et al. Once-weekly semaglutide doubles the five-year risk of nonarteritic anterior ischemic optic neuropathy in a Danish cohort of 424,152 persons with type 2 diabetes. Int J Retina Vitreous. 2024. PubMed
- DeParis SW, et al. Glucagon-Like Peptide-1 Receptor Agonists and the Risk of Non-Arteritic Anterior Ischemic Optic Neuropathy: A Consensus Statement by the North American Neuro-Ophthalmology Society and the American Academy of Ophthalmology. Ophthalmology. 2026. PubMed
- US Food and Drug Administration. FDA Requests Removal of Suicidal Behavior and Ideation Warning from Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Medications. Drug Safety Communication. FDA